Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Conditions
Glioblastoma · Malignant Glioma · Recurrent Glioblastoma · Recurrent Malignant Glioma · Recurrent Grade III Glioma · Grade III Glioma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham, Children's of Alabama, Birmingham, Alabama, United States
Children's Hospital of Los Angeles, Los Angeles, California, United States
Rady Children's Hospital, San Diego, California, United States
University of California, San Francisco, San Francisco, California, United States
Children's National Hospital, Washington D.C., District of Columbia, United States
University of Florida, Gainesville, Florida, United States
Riley Children's Hospital, Indianapolis, Indiana, United States
Johns Hopkins University, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Washington University St. Louis, St Louis, Missouri, United States
Hackensack Meridian Children's Health at Joseph M. Sanzari Children's Hospital, Hackensack, New Jersey, United States
Duke Children's Hospital & Health Center, Durham, North Carolina, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
University of Utah, Salt Lake City, Utah, United States
Sydney Children's Hospital, Sydney, New South Wales, Australia
The Children's Hospital at Westmead, Westmead, New South Wales, Australia
Queensland Children's Hospital, South Brisbane, Queensland, Australia
Women's and Children's Hospital, North Adelaide, South Australia, Australia
Royal Children's Hospital, Parkville, Victoria, Australia
Perth Children's' Hospital, Perth, Western Australia, Australia
Study leads
Tom Davidson (tdavidson@chla.usc.edu), MD
Study Chair
Children's Hospital Los Angeles
No study contact email or phone is listed for this trial.